About The Study: The findings of this study suggest that body mass index and obesity prevalence in the U.S. decreased in 2023 for the first time in more than a decade. The most notable decrease was in the South, which had the highest observed per capita glucagon-like peptide 1 receptor agonist (GLP-1RA) dispensing rate. However, dispensing does not necessarily mean uptake, and the South also experienced disproportionately high COVID-19 mortality among individuals with obesity.
Corresponding Author: To contact the corresponding author, Benjamin Rader, PhD, MPH, email benjamin.rader@childrens.harvard.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamahealthforum.2024.3685)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.3685?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=121324
About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.
JAMA Health Forum